Orforglipron vs CagriSema
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3502970, OWL833
Orforglipron is Eli Lilly's oral, once-daily GLP-1 receptor agonist, and the headline is that it is a small molecule, not a peptide, so it survives the gut and can be taken as a plain pill with no food or water restrictions. It is being developed for type 2 diabetes and obesity and has completed multiple successful Phase 3 trials. As of mid-2026 it is filed for regulatory review but not yet approved.
Also: Semaglutide + Cagrilintide
CagriSema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a GLP-1 receptor agonist, the molecule behind Ozempic and Wegovy) and cagrilintide (a long-acting amylin analog). It is being developed by Novo Nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 REDEFINE trials. It is not yet approved by the FDA, though regulatory filings are underway.
Key Comparison Insights
- Orforglipron is FDA approved, while CagriSema remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Orforglipron | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Orforglipron activates the same GLP-1 receptor that injectable drugs like semaglutide target, which curbs appetite, slows stomach emptying, and triggers insulin release when blood sugar is high. The difference is chemistry. Semaglutide is a fragile peptide that the digestive tract chews up, which is why it normally needs an injection or a specially formulated pill taken on an empty stomach. Orforglipron is a non-peptide small molecule engineered to bind the same receptor while being stable enough to swallow like any other tablet. Same biological lever, far more convenient delivery. | The combination works on two different appetite systems at once. Semaglutide mimics GLP-1, a gut hormone that boosts insulin after meals, slows stomach emptying, and signals fullness to the brain. Cagrilintide is a synthetic version of amylin, a hormone co-secreted with insulin from the pancreas, which reduces food intake and reinforces satiety through separate brain circuits in the hindbrain and hypothalamus. The idea, still being characterized, is that hitting GLP-1 and amylin pathways together produces more appetite suppression than either alone. Both components are engineered for slow release so a single weekly dose maintains steady drug levels. |
| Common Dosing | Limited community data available See research protocols | Limited community data available See research protocols |
| Administration | Oral tablet daily | Subcutaneous injection weekly |
| Typical Duration | Long-term use expected | Long-term use expected |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The evidence base here is strong and recent, anchored by large Phase 3 programs. In the obesity ATTAIN-1 trial (72 weeks), all three doses beat placebo for weight loss, and full results were published in the New England Journal of Medicine. ATTAIN-2, in adults with obesity and type 2 diabetes, was published in The Lancet and showed clinically meaningful weight loss plus improvements in waist circumference, blood pressure, non-HDL cholesterol, and triglycerides. On the diabetes side, ACHIEVE-1 was the first Phase 3 win for any oral small-molecule GLP-1 drug, and in the head-to-head ACHIEVE-3 trial orforglipron beat oral semaglutide on both A1C and weight. Side effects mirror the rest of the GLP-1 class: mostly nausea, vomiting, and diarrhea, generally mild to moderate. The realistic read is that this is a genuine breakthrough in delivery rather than a brand-new mechanism, and approval decisions are expected to follow the completed filings. | This is one of the better-tested experimental obesity drugs because it went straight into large human phase 3 trials rather than living only in animal data. In REDEFINE 1, about 3,400 adults with overweight or obesity but without diabetes were randomized over 68 weeks; CagriSema produced roughly 20.4% average body weight loss versus 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and 3.0% for placebo, with results published in the New England Journal of Medicine in 2025. REDEFINE 2 tested it in adults with type 2 diabetes and also met its endpoints, showing meaningful weight loss and HbA1c improvement compared with placebo. Notably, the headline 20% figure landed below Novo Nordisk's own 25% target, which disappointed investors even though the drug clearly worked. The most common side effects were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the GLP-1 plus amylin class. CagriSema is not FDA-approved as of mid-2026, so anything sold under that name outside a clinical setting is unregulated. |
Frequently Asked Questions: Orforglipron vs CagriSema
What is the difference between Orforglipron and CagriSema?
Orforglipron is a weight loss peptide that orforglipron is eli lilly's oral, once-daily glp-1 receptor agonist, and the headline is that it is a small molecule, not a peptide, so it survives the gut and can be taken as a plain pill with no food or water restrictions. it is being developed for type 2 diabetes and obesity and has completed multiple successful phase 3 trials. as of mid-2026 it is filed for regulatory review but not yet approved. CagriSema is a weight loss peptide that cagrisema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a glp-1 receptor agonist, the molecule behind ozempic and wegovy) and cagrilintide (a long-acting amylin analog). it is being developed by novo nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 redefine trials. it is not yet approved by the fda, though regulatory filings are underway. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Orforglipron or CagriSema?
Neither is universally "better" - the choice depends on your specific goals. Orforglipron is typically used for weight loss purposes, while CagriSema is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Orforglipron and CagriSema be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Orforglipron and CagriSema together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.